Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) CMO David Shapiro Sells 553 Shares

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) CMO David Shapiro sold 553 shares of the firm’s stock in a transaction on Tuesday, July 11th. The shares were sold at an average price of $124.01, for a total transaction of $68,577.53. Following the transaction, the chief marketing officer now owns 44,562 shares in the company, valued at approximately $5,526,133.62. The transaction was disclosed in a document filed with the SEC, which is available at this link.

David Shapiro also recently made the following trade(s):

  • On Tuesday, August 1st, David Shapiro sold 1,118 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $119.00, for a total transaction of $133,042.00.
  • On Monday, July 3rd, David Shapiro sold 350 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $121.24, for a total transaction of $42,434.00.
  • On Monday, May 1st, David Shapiro sold 1,117 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $112.18, for a total transaction of $125,305.06.

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) traded up 2.05% on Friday, reaching $103.19. 343,264 shares of the company were exchanged. The company’s market cap is $2.59 billion. Intercept Pharmaceuticals, Inc. has a 12 month low of $96.63 and a 12 month high of $172.95. The company’s 50-day moving average price is $121.60 and its 200 day moving average price is $117.79.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The company had revenue of $30.89 million for the quarter, compared to the consensus estimate of $27.50 million. During the same quarter in the prior year, the company earned ($3.14) earnings per share. Intercept Pharmaceuticals’s revenue was up 459.6% on a year-over-year basis. On average, equities research analysts expect that Intercept Pharmaceuticals, Inc. will post ($14.05) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) CMO David Shapiro Sells 553 Shares” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2017/08/11/david-shapiro-sells-553-shares-of-intercept-pharmaceuticals-inc-nasdaqicpt-stock-updated-updated-updated.html.

Several equities analysts recently issued reports on ICPT shares. Cowen and Company reissued a “buy” rating and set a $225.00 price target on shares of Intercept Pharmaceuticals in a report on Monday, April 24th. Zacks Investment Research downgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 1st. Oppenheimer Holdings, Inc. set a $200.00 target price on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 4th. Cantor Fitzgerald set a $60.00 target price on shares of Intercept Pharmaceuticals and gave the stock a “sell” rating in a research note on Thursday, May 4th. Finally, Laidlaw raised shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $115.00 target price for the company in a research note on Friday, May 5th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $203.67.

Several hedge funds and other institutional investors have recently bought and sold shares of ICPT. FMR LLC increased its position in Intercept Pharmaceuticals by 0.7% in the second quarter. FMR LLC now owns 3,750,678 shares of the biopharmaceutical company’s stock valued at $454,094,000 after buying an additional 25,958 shares during the period. Vanguard Group Inc. increased its stake in shares of Intercept Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after buying an additional 57,149 shares during the period. State Street Corp increased its stake in shares of Intercept Pharmaceuticals by 7.3% in the first quarter. State Street Corp now owns 805,550 shares of the biopharmaceutical company’s stock valued at $91,110,000 after buying an additional 54,523 shares during the period. First Trust Advisors LP increased its stake in shares of Intercept Pharmaceuticals by 17.0% in the second quarter. First Trust Advisors LP now owns 287,411 shares of the biopharmaceutical company’s stock valued at $34,797,000 after buying an additional 41,856 shares during the period. Finally, Macquarie Group Ltd. increased its stake in shares of Intercept Pharmaceuticals by 54.2% in the first quarter. Macquarie Group Ltd. now owns 241,565 shares of the biopharmaceutical company’s stock valued at $27,321,000 after buying an additional 84,954 shares during the period. 83.93% of the stock is currently owned by hedge funds and other institutional investors.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

What are top analysts saying about Intercept Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intercept Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit